Drug intelligence / Profile preview

ENV-375

Development stage: Preclinical
Lead developer: Envisagenics
Modality: RNA Therapeutics → Nucleic Acid Therapeutics

Overview

ENV-375 is an early-stage therapeutic candidate developed by Envisagenics for the treatment of neurodegenerative diseases, including Frontotemporal Dementia (FTD), Alzheimer's Disease (AD), and Parkinson's Disease (PD). The candidate was identified using Envisagenics' proprietary SpliceCore® platform, which utilizes artificial intelligence and high-performance computing to discover disease-causing alternative RNA splicing events. ENV-375 is designed to target specific RNA splicing errors associated with protein aggregation and neuronal loss in CNS disorders. As of early 2024, the program is in the preclinical development phase, progressing from in silico discovery through experimental validation.

Targets

Pre-messenger RNA splice sites

Beyond the preview

Go deeper on ENV-375.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENV-375.

Explore the full profile